Creative Biolabs utilizes advanced formulation techniques to ensure the stability of our liposome-antibody conjugates, allowing for prolonged circulation times and improved bioavailability. Our liposomes can be engineered to precisely target specific tissues or organs, making your therapeutic agents more effective and reducing off-target effects.

Introduction

Antibody-conjugated liposomes are lipid-based nanoparticles designed to encapsulate therapeutic agents while being modified with antibodies that specifically target cell surface antigens. This targeted delivery system is especially advantageous for treating diseases that necessitate localized therapy, including cancer, autoimmune disorders, and infections.

By attaching antibodies to the liposome surface, Creative Biolabs can enhance biocompatibility and ensure the precise delivery of therapeutic agents to intended sites. Our services can reduce systemic toxicity and improve therapeutic efficacy.

Fig.1 Liposomes Types.^1,3

Services

Creative Biolabs is proud to offer customized liposome-coupled antibody services for a variety of targeted applications, including tumor tissues, the central nervous system (CNS), the cardiovascular system, the immune system, the liver, the pancreas, breast, lung, kidney, and spleen.

Our tumor-targeting solutions enhance specificity and minimize off-target effects, maximizing therapeutic efficacy while reducing side effects. Our CNS-targeting liposomes enable effective treatment of neurological disorders by facilitating the crossing of the blood-brain barrier. In the cardiovascular realm, our service promotes targeted drug delivery, improving the potential for vascular therapies.

For immune system applications, our liposome-antibody conjugates selectively modulate immune responses, offering innovative immunotherapy solutions. Our liver-targeting liposomes enhance the therapeutic index for hepatic diseases, while formulations designed for the pancreas improve treatment outcomes for metabolic disorders. Additionally, our targeting strategies for breast, lung, and kidney tissues optimize accumulation in specific sites, increasing treatment effectiveness and minimizing systemic toxicity. We are dedicated to delivering cutting-edge solutions tailored to your research and therapeutic needs.

Fig.2 Liposomes for Drug Delivery.^2,3

Advantages

• Specificity: Antibody-liposomes can be designed to bind specifically to particular tissues or organs, enhancing drug delivery to targeted areas while minimizing off-target effects.
• Enhanced Pharmacokinetics: Targeting specific tissues can optimize the pharmacokinetic profile of drugs, leading to prolonged circulation times and higher local concentrations at the target site.
• Multi-functionalization: Liposomes can be modified with multiple functionalities, such as imaging agents or additional targeting moieties, enabling simultaneous diagnosis and therapy (theranostics).
• Sustained Release: Liposomal formulations can be engineered for controlled or sustained release, providing a prolonged therapeutic effect over time.
• Ability to Overcome Biological Barriers: Targeted liposomes can help to overcome physiological barriers (like BBB) that hinder the effective delivery of therapeutic agents.

Application

• Liver Targeting

Our laboratory has developed liposomes modified with anti-ASGPR (Asialoglycoprotein Receptor) antibodies to effectively target the liver, enabling precise delivery of therapeutics such as nucleic acids and chemotherapeutics directly to hepatic cells.

• Tumor Targeting

Multiple studies have shown that liposomes conjugated with antibodies against tumor-associated antigens significantly enhance the delivery of chemotherapeutic agents to cancer cells. This strategy has been successfully applied in treating breast cancer, leukemia, and other malignancies, leading to improved therapeutic outcomes and reduced off-target toxicity.

• Cardiovascular Applications

Our team has initiated a project involving liposomes that target specific vascular markers, such as integrins, to deliver therapeutics for cardiovascular diseases. These targeted liposomes aim to enhance drug distribution within affected tissues, such as atherosclerotic plaques.

• Autoimmune Disorders
• We have also developed liposome formulations with antibodies that selectively target immune cells for the delivery of immunosuppressive drugs. This system is designed to regulate the immune response in conditions like rheumatoid arthritis and lupus.
• Neurological Disorders

Targeting the blood-brain barrier (BBB) presents a considerable challenge for drug delivery in neurological disorders. To address this, we are investigating liposomes modified with antibodies against BBB transporters to facilitate the delivery of therapeutic molecules across this barrier.

Creative Biolabs specializes in providing targeted liposome-antibody conjugation services targeting different tissues and organs. Our cutting-edge technology not only improves the efficacy of drug delivery but also minimizes side effects, offering you a pathway to more effective treatments. We employ state-of-the-art characterization methods to analyze the quality and performance of our conjugates, ensuring that you receive products that meet the highest standards. Please feel free to contact us to learn more about our targeted liposome-antibody conjugation services.

For research use only. Not intended for any clinical use.